Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease
Top Cited Papers
- 25 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (6), 6887-6896
- https://doi.org/10.1021/acsnano.0c01018
Abstract
Rosmarinic acid (RA), one of the most important polyphenol-based antioxidants, has received growing interest because of its bioactive properties, including anti-inflammatory, anticancer, and antibacterial activities. Despite such high therapeutic potential of RA, intrinsic properties of poor water solubility and low bioavailability have limited its translation into the clinic. Here, we report on the synthesis and preparation of PEGylated RA-derived nanoparticles (RANPs) and their use as a therapeutic nanomedicine for treatment of inflammatory bowel disease (IBD) in a dextran sulfate sodium (DSS)-induced acute colitis mouse model. PEGylated RA, synthesized via a one-step process from RA and a PEG-containing amine, self-assembled in buffer to form nanoparticles (RANPs) with a diameter of 63.5 ± 4.0 nm. The resulting RANPs showed high colloidal stability in physiological medium up to 2 weeks. RANPs were capable of efficiently scavenging H2O2, thereby protecting cells from H2O2-induced damage. Furthermore, the corticosteroid drug, dexamethasone (DEX), could be loaded into RANPs and released in response to a reactive oxygen species (ROS) stimulus. Intravenously administered RANPs exhibited significantly improved pharmacokinetic parameters compared with those of the parent RA and were preferentially localized to the inflamed colon. Intravenous administration of RANPs in DSS-induced colitis mice substantially mitigated colonic inflammation in a dose-dependent manner compared with the parent RA, as evidenced by significantly reduced disease activity index (DAI) scores, body weight loss, and colonic inflammatory damage. In addition, RANPs suppressed expression and production of typical pro-inflammatory cytokines in the inflamed colon. Furthermore, DEX-loaded RANPs showed enhanced therapeutic efficacy in the colitis model compared with bare RANPs at the equivalent dose, indicating synergy with a conventional medication. These findings suggest that RANPs deserve further consideration as a potential therapeutic nanomedicine for the treatment of various inflammatory diseases, including IBD.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018M3A9B5023527, NRF-2018R1A3B1052661)
This publication has 43 references indexed in Scilit:
- Naturally Occurring Bioactive Compound‐Derived Nanoparticles for Biomedical ApplicationsAdvanced Therapeutics, 2019
- Black Pigment Gallstone Inspired Platinum‐Chelated Bilirubin Nanoparticles for Combined Photoacoustic Imaging and Photothermal Therapy of CancersAngewandte Chemie International Edition, 2017
- Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of NanoparticlesACS Nano, 2017
- Multistimuli‐Responsive Bilirubin Nanoparticles for Anticancer TherapyAngewandte Chemie International Edition, 2016
- Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM)Advances in Colloid and Interface Science, 2015
- Accelerating the Translation of Nanomaterials in BiomedicineACS Nano, 2015
- Nanotechnology-based drug delivery systems and herbal medicines: a reviewInternational Journal of Nanomedicine, 2013
- Curcumin nanoformulations: a future nanomedicine for cancerDrug Discovery Today, 2011
- Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with FlavonoidsCurrent Medicinal Chemistry, 2010
- Layer-by-Layer-Coated Gelatin Nanoparticles as a Vehicle for Delivery of Natural PolyphenolsACS Nano, 2009